4.7 Review

The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery

Journal

NANOMEDICINE
Volume 11, Issue 1, Pages 81-100

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/nnm.15.188

Keywords

immune response; nano-bio interface; nanomedicine; nanoparticles; protein corona; targeting; toxicity

Funding

  1. Italian Ministry of Health [RF-2010-2318372, RF-2010-2305526]
  2. NIH/NCI [1R21CA173579-01A1]
  3. Pilot project from NIH/NCI [5U54CA143837 PSOC]
  4. BCRP Innovator Expansion from Department of Defence [W81XWH-12-10414]
  5. Regenerative Medicine Program Cullen Trust for Health Care
  6. POR Campania FSE Project DIAINTECH, Italy
  7. NATIONAL CANCER INSTITUTE [U54CA143837, R21CA173579] Funding Source: NIH RePORTER

Ask authors/readers for more resources

In a perfect sequence of events, nanoparticles (NPs) are injected into the bloodstream where they circulate until they reach the target tissue. The ligand on the NP surface recognizes its specific receptor expressed on the target tissue and the drug is released in a controlled manner. However, once injected in a physiological environment, NPs interact with biological components and are surrounded by a protein corona (PC). This can trigger an immune response and affect NP toxicity and targeting capabilities. In this review, we provide a survey of recent findings on the NP-PC interactions and discuss how the PC can be used to modulate both cytotoxicity and the immune response as well as to improve the efficacy of targeted delivery of nanocarriers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available